555 related articles for article (PubMed ID: 24523569)
1. The inflammatory chemokine CCL5 and cancer progression.
Aldinucci D; Colombatti A
Mediators Inflamm; 2014; 2014():292376. PubMed ID: 24523569
[TBL] [Abstract][Full Text] [Related]
2. Inhibition of the CCL5/CCR5 Axis against the Progression of Gastric Cancer.
Aldinucci D; Casagrande N
Int J Mol Sci; 2018 May; 19(5):. PubMed ID: 29772686
[TBL] [Abstract][Full Text] [Related]
3. CC chemokine receptor 5: the interface of host immunity and cancer.
de Oliveira CE; Oda JM; Losi Guembarovski R; de Oliveira KB; Ariza CB; Neto JS; Banin Hirata BK; Watanabe MA
Dis Markers; 2014; 2014():126954. PubMed ID: 24591756
[TBL] [Abstract][Full Text] [Related]
4. Expression of CCL5 (RANTES) and CCR5 in prostate cancer.
Vaday GG; Peehl DM; Kadam PA; Lawrence DM
Prostate; 2006 Feb; 66(2):124-34. PubMed ID: 16161154
[TBL] [Abstract][Full Text] [Related]
5. The potential to target CCL5/CCR5 in breast cancer.
Velasco-Velázquez M; Xolalpa W; Pestell RG
Expert Opin Ther Targets; 2014 Nov; 18(11):1265-75. PubMed ID: 25256399
[TBL] [Abstract][Full Text] [Related]
6. Cytokine CCL5 and receptor CCR5 axis in glioblastoma multiforme.
Kranjc MK; Novak M; Pestell RG; Lah TT
Radiol Oncol; 2019 Nov; 53(4):397-406. PubMed ID: 31747383
[TBL] [Abstract][Full Text] [Related]
7. CCR5-Mediated Signaling Is Involved in Invasion of Glioblastoma Cells in Its Microenvironment.
Novak M; Koprivnikar Krajnc M; Hrastar B; Breznik B; Majc B; Mlinar M; Rotter A; Porčnik A; Mlakar J; Stare K; Pestell RG; Lah Turnšek T
Int J Mol Sci; 2020 Jun; 21(12):. PubMed ID: 32545571
[TBL] [Abstract][Full Text] [Related]
8. CCL5/CCR5 axis induces vascular endothelial growth factor-mediated tumor angiogenesis in human osteosarcoma microenvironment.
Wang SW; Liu SC; Sun HL; Huang TY; Chan CH; Yang CY; Yeh HI; Huang YL; Chou WY; Lin YM; Tang CH
Carcinogenesis; 2015 Jan; 36(1):104-14. PubMed ID: 25330803
[TBL] [Abstract][Full Text] [Related]
9. Role of CCL5 in invasion, proliferation and proportion of CD44+/CD24- phenotype of MCF-7 cells and correlation of CCL5 and CCR5 expression with breast cancer progression.
Zhang Y; Yao F; Yao X; Yi C; Tan C; Wei L; Sun S
Oncol Rep; 2009 Apr; 21(4):1113-21. PubMed ID: 19288016
[TBL] [Abstract][Full Text] [Related]
10. The CCL5/CCR5 Axis in Cancer Progression.
Aldinucci D; Borghese C; Casagrande N
Cancers (Basel); 2020 Jul; 12(7):. PubMed ID: 32630699
[TBL] [Abstract][Full Text] [Related]
11.
Battaglin F; Baca Y; Millstein J; Yang Y; Xiu J; Arai H; Wang J; Ou FS; Innocenti F; Mumenthaler SM; Jayachandran P; Kawanishi N; Lenz A; Soni S; Algaze S; Zhang W; Khoukaz T; Roussos Torres E; Seeber A; Abraham JP; Lou E; Philip PA; Weinberg BA; Shields AF; Goldberg RM; Marshall JL; Venook AP; Korn WM; Lenz HJ
J Immunother Cancer; 2024 Jan; 12(1):. PubMed ID: 38212126
[TBL] [Abstract][Full Text] [Related]
12. Importance of the CCR5-CCL5 axis for mucosal Trypanosoma cruzi protection and B cell activation.
Sullivan NL; Eickhoff CS; Zhang X; Giddings OK; Lane TE; Hoft DF
J Immunol; 2011 Aug; 187(3):1358-68. PubMed ID: 21715689
[TBL] [Abstract][Full Text] [Related]
13. Stromal CCL5 Promotes Breast Cancer Progression by Interacting with CCR3 in Tumor Cells.
Yamaguchi M; Takagi K; Narita K; Miki Y; Onodera Y; Miyashita M; Sasano H; Suzuki T
Int J Mol Sci; 2021 Feb; 22(4):. PubMed ID: 33671956
[TBL] [Abstract][Full Text] [Related]
14. Metastasis Suppressors Regulate the Tumor Microenvironment by Blocking Recruitment of Prometastatic Tumor-Associated Macrophages.
Frankenberger C; Rabe D; Bainer R; Sankarasharma D; Chada K; Krausz T; Gilad Y; Becker L; Rosner MR
Cancer Res; 2015 Oct; 75(19):4063-73. PubMed ID: 26238785
[TBL] [Abstract][Full Text] [Related]
15. Expression and biological functions of the CCL5-CCR5 axis in oral lichen planus.
Shan J; Li S; Wang C; Liu L; Wang X; Zhu D; Fan Y; Xu J
Exp Dermatol; 2019 Jul; 28(7):816-821. PubMed ID: 31006151
[TBL] [Abstract][Full Text] [Related]
16. CR5/CCL5 axis is linked to a poor outcome, and inhibition reduces metastasis in oral squamous cell carcinoma.
González-Arriagada WA; Coletta RD; Lozano-Burgos C; García C; Maripillán J; Alcayaga-Miranda F; Godínez-Pacheco B; Oyarce-Pezoa S; Martínez-Flores R; García IE
J Cancer Res Clin Oncol; 2023 Dec; 149(19):17335-17346. PubMed ID: 37831273
[TBL] [Abstract][Full Text] [Related]
17. CCL5-armed oncolytic virus augments CCR5-engineered NK cell infiltration and antitumor efficiency.
Li F; Sheng Y; Hou W; Sampath P; Byrd D; Thorne S; Zhang Y
J Immunother Cancer; 2020 Feb; 8(1):. PubMed ID: 32098828
[TBL] [Abstract][Full Text] [Related]
18. Breast Phyllodes Tumors Recruit and Repolarize Tumor-Associated Macrophages via Secreting CCL5 to Promote Malignant Progression, Which Can Be Inhibited by CCR5 Inhibition Therapy.
Nie Y; Huang H; Guo M; Chen J; Wu W; Li W; Xu X; Lin X; Fu W; Yao Y; Zheng F; Luo ML; Saw PE; Yao H; Song E; Hu H
Clin Cancer Res; 2019 Jul; 25(13):3873-3886. PubMed ID: 30890553
[TBL] [Abstract][Full Text] [Related]
19. CCR5 antagonist blocks metastasis of basal breast cancer cells.
Velasco-Velázquez M; Jiao X; De La Fuente M; Pestell TG; Ertel A; Lisanti MP; Pestell RG
Cancer Res; 2012 Aug; 72(15):3839-50. PubMed ID: 22637726
[TBL] [Abstract][Full Text] [Related]
20. Naming the Barriers between Anti-CCR5 Therapy, Breast Cancer and Its Microenvironment.
Brett E; Duscher D; Pagani A; Daigeler A; Kolbenschlag J; Hahn M
Int J Mol Sci; 2022 Nov; 23(22):. PubMed ID: 36430633
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
